News | February 27, 2022
Daewoong completes combination therapy of antidiabetic drug Enavogliflozin
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated
